- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05473884
Lesion Preparation in Femoropopliteal Artery Occlusion Disease (CIVILIAN)
November 2, 2022 updated by: Bo Yu, MD, Shanghai Pudong Hospital
CIVILIAN Study in Femoropopliteal Artery Occlusion Disease
Peripheral arterial disease (PAD) carries a significant global health burden, and can limit functional capacity and quality of life.
Percutaneous transluminal angioplasty (PTA) for PAD is often associated with suboptimal outcomes due to complications following balloon inflation related to vessel trauma and flow limiting dissections that may require bailout stenting.
Different strategies and techniques to enhance both acute and longer-term outcomes with drug-coated balloons (DCB) are needed.
This is a national, prospective, multi-center, non-randomized, real-world study to evaluate the safety and efficacy of multiple vessel preparation strategies combined with drug-coating balloon (DCB) in Femoropopliteal Artery (F-PA) lesions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Femoropopliteal artery occlusive disease is a common type of peripheral arterial disease (PAD).
Hitherto, endovascular treatment has been testified and advocated as the first-line treatment of femoropopliteal occlusive disease.
However, the in-stent restenosis has been a major limitation of well long-term patency rate in this segment due to physiological and geometrical issues.
The concept "leave nothing behind" is proposed, and some vessel preparation methods and devices, such as directional atherectomy, rotational atherectomy, laser atherectomy are developed.
This is a national, prospective, multi-center, non-randomized study to evaluate the safety and efficacy of multiple vessel preparation strategies combined with drug-coating balloon (DCB) in Femoropopliteal Artery (F-PA) lesions.
A total of 1000 patients will be included in approximately 8 sites.
The study is designed to demonstrate the inferiority of different vessel preparation strategies in various fields under long-term follow-up.
Study Type
Observational
Enrollment (Anticipated)
800
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bo Yu, M.D.
- Phone Number: 18918922698
- Email: paul.yubo@gmail.com
Study Contact Backup
- Name: Weihao Shi, M.D.
- Phone Number: 13601982603
- Email: vascular741021@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201200
- Recruiting
- Shanghai Pudong Hospital
-
Contact:
- Weihao Shi, M.D.
- Phone Number: 13601982603
- Email: vascular741021@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No
Description
General Inclusion Criteria:
- Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form
- Patient has a score from 2 to 5 following Rutherford classification
- Unilateral or bilateral F-P occlusive lesions (enrollment of one or both target limbs depend on operators)
- Complete recanalization followed by POBA, Chocolate PTA, Scoring PTA, Shockwave PTA, SilverHawk, TurboHawk, Jetstream, Angiojet, Laser and Rotarex
Angiographic Inclusion Criteria:
- TASC II-Type A/B/C/D
- Iliac inflow interventions can be done at the discretion of the investigator with standard balloon Percutaneous Transluminal Angioplasty (PTA)-less than 50% residual stenosis
- There is angiographic evidence of at least one-vessel-runoff (>10cm) to the foot
General Exclusion Criteria:
- Projected for major amputation of target limb (above ankle joint)
- Change to thrombectomy or bypass during operation
- Patients for whom antiplatelet therapy, anticoagulants, medium contrast, or thrombolytic drugs are contraindicated
- Patient has bleeding diathesis, coagulopathy, known hypercoagulable condition or refuses blood transfusion
- female patient with childbearing potential not taking adequate contraceptives or currently breastfeeding.
- Life expectancy of less than twelve months.
- Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
- Patient presenting one of the following comorbid conditions: hemodialysis, elevated creatine levels (> 2.5mg/dl), recent MI or ischemic stroke occurrence (both within 30 days).
- Patient unwilling or unlikely to comply with Follow-Up schedule
Angiographic Exclusion Criteria:
- Testified for acute F-P arterial embolization
- Thromboangiitis obliterans
- Failed for recanalization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
lesion preparation with POBA in femoropopliteal Artery occlusion
Patients with femoropopliteal artery occlusion were treated by plain old balloon angioplasty followed with DCB.
|
Lumen gain is achieved by plain old balloon angioplasty under working inflation pressure.
|
lesion preparation with debulking devices in femoropopliteal Artery occlusion
Patients with femoropopliteal artery occlusion were treated by other lesion preparation devices, like Chocolate balloon, Shockwave balloon, TurboHawk, Jetstream and Rotarex and then followed by DCB.
|
successful recanalization of femoropopliteal artery occlusion and then followed by lesion preparation devices and plain old balloon angioplasty
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from TLR
Time Frame: within 12 months post-procedure
|
Percentage of participants with a 1-year TLR free survival
|
within 12 months post-procedure
|
Incidence of complications
Time Frame: immediately following procedure (day 30)
|
Procedure-related complications at day 30, defined as: procedure-related distal embolization, acute post-procedural target vessel thrombosis, bleeding, perforation, acute renal failure
|
immediately following procedure (day 30)
|
Major adverse event
Time Frame: within 12 months post-procedure
|
Major adverse events (MAE) rate at 1 year, defined as: Myocardial Infarction (MI), major amputation, all-cause mortality
|
within 12 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: within 24 hours post-procedure
|
Technical success, defined as the ability to cross the target lesion with the device, set up antegrade blood flow and leave residual stenosis <30%
|
within 24 hours post-procedure
|
Incidence of dissection and types
Time Frame: immediately following vessel preparation
|
Dissection patterns according to the National Heart, Lung and Blood Institute classification system for the coronary artery.
(Type A-F) (A) Type A has minor radiolucent areas, (B) type B is a linear dissection, (C) type C has contrast outside the lumen, (D) type D is a spiral dissection, (E) type E has persistent filling defects, and (F) type F is a total occlusion without distal antegrade flow
|
immediately following vessel preparation
|
Incidence of Bailout stenting
Time Frame: immediately following vessel preparation and DCB angioplasty
|
Bailout stenting, defined as stent implantation after vessel preparation and DCB including bare metal stents (BMS), covered stents and drug-eluting stents (DES)
|
immediately following vessel preparation and DCB angioplasty
|
Amputation Free Survival
Time Frame: within 12 months post-procedure
|
Percentage of participants with a 1-year amputation free survival
|
within 12 months post-procedure
|
Numbers of patients with Primary patency
Time Frame: within 3, 6, 12 months post-procedure
|
Primary patency rate at 6, 12, 24 months as determined by Duplex ultrasound at six months, defined as a target vessel with <50% diameter stenosis (systolic velocity ratio no greater than 2.4), without occurrence of target lesion revascularization between the index procedure and follow-up control
|
within 3, 6, 12 months post-procedure
|
Improvement of ABI
Time Frame: within 3, 6, 12 months post-procedure
|
Increase of Ankle-Brachial Index (ABI) at 12, 24 months, defined as: an increase in ABI compared to baseline
|
within 3, 6, 12 months post-procedure
|
Improvement of related symptoms
Time Frame: within 3, 6, 12 months post-procedure
|
related symptoms could be identified as Rutherford classification from level 1-6. improvement in Rutherford classification compared to the pre-procedure Rutherford classification |
within 3, 6, 12 months post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2022
Primary Completion (ANTICIPATED)
May 31, 2024
Study Completion (ANTICIPATED)
May 31, 2024
Study Registration Dates
First Submitted
July 18, 2022
First Submitted That Met QC Criteria
July 22, 2022
First Posted (ACTUAL)
July 26, 2022
Study Record Updates
Last Update Posted (ACTUAL)
November 7, 2022
Last Update Submitted That Met QC Criteria
November 2, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Shanghai-CIVILIAN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In-stent Restenosis
-
Boston Scientific CorporationActive, not recruiting
-
Klinikum CoburgUnknown
-
Assiut UniversityNot yet recruiting
-
Luzerner KantonsspitalUnknown
-
Fundación Médica para la Investigación y Desarrollo...Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SAUnknown
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
-
Seoul National University HospitalUnknownIn-stent Restenosis LesionKorea, Republic of
-
Midwest Cardiovascular Research FoundationCompletedFemoropopliteal In-stent RestenosisUnited States
-
Spanish Society of CardiologyAbbott Medical Devices; Terumo Medical Corporation; Fundación de Investigación... and other collaboratorsUnknownCoronary In-stent RestenosisSpain
Clinical Trials on conventional balloon
-
Stephane CarlierBrosMed Medical Co., Ltd; University of MonsRecruiting
-
North Texas Veterans Healthcare SystemBoston Scientific CorporationCompletedPERIPHERAL VASCULAR DISEASEUnited States
-
Klinikum RosenheimCharite University, Berlin, Germany; Medtronic; University Hospital Tuebingen; Herz-Zentrums... and other collaboratorsUnknown
-
Konkuk University Medical CenterUnknownVascular Graft Anastomotic Stenosis
-
Centre Leon BerardTerminatedSolid Tumors | Spine MetastasisFrance
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Meshalkin Research Institute of Pathology of CirculationRecruitingCoronary Artery DiseaseRussian Federation
-
Shanghai 10th People's HospitalUnknownPeripheral Arterial DiseaseChina
-
Hospital Universitario La FeRecruitingCoronary Artery Disease | Percutaneous Coronary Intervention | Cutting BalloonSpain
-
Helsinki University Central HospitalCompletedVascular Access Complication | Restenosis, Vascular Graft | Dialysis Related Complications